Business · 19/05/2004
FDA Extends Comment Period for Piroctone Olamine Review
The FDA is extending the comment period for its review of piroctone olamine, a potential ingredient for treating dandruff, until August 16, 2004, to allow more time for public input and data submission.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →